A secondary analysis of the SELECT trial indicates that frailty did not prevent adults with cardiovascular disease and overweight or obesity from benefiting from semaglutide, the medication marketed as Wegovy.
The analysis, reported by MedPage Today, found that by week 104, semaglutide was associated with benefits regardless of frailty status. The findings suggest that frailty alone should not disqualify patients from considering the drug.
The report is a secondary analysis of a larger trial, so it is not definitive on its own. Still, it adds to the evidence that semaglutide may have cardiovascular benefits in a wider range of patients.